NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that it has entered into a new agreement with FUJIFILM RI Pharma Co., Ltd. (FRI) to license and distribute Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) and Neurolite® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection) in Japan. Under the terms of the 10-year agreement effective January 1, 2013, which immediately follows an earlier 10-year agreement with FRI, Lantheus will continue to supply FRI with Cardiolite® and Neurolite® in finished form as well as provide the raw materials to manufacture and sell the products in unit dose form. Cardiolite® and Neurolite® are technetium-based radiopharmaceutical imaging agents used in single-photon emission computed tomography (SPECT).
